Evaluation of a real-time nucleic acid sequence-based amplification assay using molecular beacons for detection of human immunodeficiency virus type 1.
We evaluated the performance characteristics of a new, real-time nucleic acid sequence-based amplification (NASBA) assay that incorporates molecular beacon technology for detection of human immunodeficiency virus type 1 (HIV-1). The quantitative results were comparable to those obtained with three leading commercially available assays. The analytical sensitivity was 37 IU/ml. The NASBA assay detected clinically relevant recombinant viruses and all group M HIV-1 subtypes.
McClernon
D R
DR
Clinical Virology Department, GlaxoSmithKline, Research Triangle Park, NC 27709-3398, USA. daniel.r.mcclernon@gsk.com
Vavro
C
C
St Clair
M
M
D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D015335:Molecular Probes; D012367:RNA, Viral / Q000032:analysis / Q000302:isolation & purification; D011933:Reagent Kits, Diagnostic; D011995:Recombination, Genetic; D021161:Self-Sustained Sequence Replication / Q000295:instrumentation / Q000379:methods*; D012680:Sensitivity and Specificity
D015335:Molecular Probes; D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic